Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Aug 11;228(3):299-310.
doi: 10.1093/infdis/jiad024.

Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial

Zourab Bebia  1 , Osvaldo Reyes  2 , Robert Jeanfreau  3 , Anu Kantele  4 , Ruth Graciela De Leon  5 , Marta García Sánchez  6 , Peyman Banooni  7 , Glenn J Gardener  8 , José Luis Bartha Rasero  9 , Maria Begoña Encinas Pardilla  10 , Joanne M Langley  11 , Claudio Maañón Di Leo  12 , Elisabeth Botelho-Nevers  13 , Jim Buttery  14 , Helene Laurichesse  15 , Shabir A Madhi  16 , Adrián Martín García  17 , Thorsten Stanley  18 , Tiphaine Barjat  19 , Rebecca Griffith  20 , Maria Mercedes Castrejón-Alba  21 , Magali de Heusch  22 , Ilse Dieussaert  23 , Melanie Hercor  22 , Patricia Lese  1 , Hui Qian  1 , Antonella N Tullio  1 , Ouzama Henry  1
Affiliations
Clinical Trial

Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial

Zourab Bebia et al. J Infect Dis. .

Abstract

Background: In a phase 1/2 study, a maternal respiratory syncytial virus vaccine candidate (RSVPreF3) demonstrated an acceptable safety profile and efficiently increased RSV-specific humoral immune responses in non-pregnant women.

Methods: In this phase 2 observer-blind, placebo-controlled, randomized clinical trial (NCT04126213), the safety of RSVPreF3 (60 or 120 µg), administered during late second or third trimester, was evaluated in 213 18- to 40-year-old healthy pregnant women through 6 months postdelivery and their offspring through infancy; immunogenicity was evaluated through day 43 postdelivery and day 181 postbirth, respectively.

Results: RSVPreF3 was well tolerated. No pregnancy-related or neonatal adverse events of special interest were considered vaccine/placebo related. In the 60 and 120 µg RSVPreF3 groups: (1) neutralizing antibody (nAb) titers in mothers increased 12.7- and 14.9-fold against RSV-A and 10.6- and 13.2-fold against RSV-B, respectively, 1 month postvaccination and remained 8.9-10.0-fold over prevaccination at day 43 postdelivery; (2) nAb titers were consistently higher compared to placebo recipients; (3) placental transfer ratios for anti-RSVPreF3 antibodies at birth were 1.62 and 1.90, respectively, and (4) nAb levels in infants were highest at birth and declined through day 181 postbirth.

Conclusions: RSVPreF3 maternal vaccination had an acceptable safety risk profile and induced robust RSV-specific immune responses with successful antibody transfer to their newborns.

Clinical trials registration: NCT04126213.

Keywords: RSV; fetal care; humoral immunity; maternal immunization; neonatal care; passive immunization; placental transfer; pregnancy; preterm birth.

Plain language summary

What is the context?: Infants, especially those less than 6 months of age, are at increased risk of lung infection caused by respiratory syncytial virus (RSV). However, this risk could be reduced with maternal vaccination against RSV during pregnancy. A previous clinical trial found that a vaccine candidate (named RSVPreF3) was well tolerated when given to non-pregnant women.

What is new?: In pregnant women, RSVPreF3 was also well tolerated. Occurrence of unsolicited adverse events was similar between vaccine and placebo recipients. None of the serious adverse events or events of interest for pregnant women or newborns were considered related to the study intervention. One month after vaccination, mothers who received RSVPreF3 had 11–15 times higher levels of antibodies against RSV than before vaccination. These antibody levels remained similar until 43 days after delivery. In the infants born to mothers vaccinated during pregnancy with RSVPreF3, antibody levels were highest at birth, when levels were higher than in their mothers, and declined through day 181 postbirth.

What is the impact?: RSVPreF3 had an acceptable safety risk profile in pregnant women and their babies. This vaccine induced potent immune responses against RSV, with maternal antibodies transferred to infants of the vaccinated mothers.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. A. N. T., H. Q., I. D., M. H., M. d. H., O. H., P. L., M. M. C., and Z. B. are or were employees of the GSK group of companies at the time of the study. A. N. T., I. D., M. d. H., M. M. C., and O. H. report holding shares of the GSK group of companies. P. L. reports personal fees from GSK. O. R. declares personal fees from CEVAXIN during the conduct of the study and outside the submitted work. A. K. declares institutional financial support from GSK for conducting this study; investigator-initiated grants from Valneva and Pfizer, the latter two outside this study; and declares no personal fees from any vaccine companies. M. G. S. declares personal fees and institutional financial support from GSK during the conduct of the study. J. M. L. declares holding the Canadian Institutes of Health Research-GSK Chair in Pediatric Vaccinology at Dalhousie University; institutional financial support from GSK during the conduct of the study; other compensation from Immunovaccine; and grants from Novavax, Janssen, and Regeneron, outside the submitted work; in all cases these are paid to Dalhousie University. J. B. declares institutional financial support from GSK, Pfizer, and MedImmune during the conduct of the study and outside the submitted work. S. A. M. has received institution grants and personal fees from BMGF and GSK; and institution grants from Pfizer, Novavax, AstraZeneca, and Minervax during the conduct of the study. R. G. declares personal fees from Optimal Clinical Trials during the conduct of the study. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Study design. Abbreviations: AE, adverse event; AESI, adverse event of special interest; MA-AE, medically attended AE; MA-RTI, medically attended respiratory tract infection; N, number of participants; RSVPreF3, respiratory syncytial virus prefusion protein vaccine; RTI, respiratory tract infection; SAE, serious adverse event. aOnly SAEs related to study participation were recorded from day −28 until vaccination; from vaccination through study end, all SAEs were recorded; b207 infants were delivered but 1 woman refused infant participation.
Figure 2.
Figure 2.
Flow diagram of mothers (A) and infants (B) participating in the study. Note, some participants were assigned >1 elimination code. Abbreviation: N, number of participants; RSVPreF3, respiratory syncytial virus prefusion protein vaccine.
Figure 2.
Figure 2.
Flow diagram of mothers (A) and infants (B) participating in the study. Note, some participants were assigned >1 elimination code. Abbreviation: N, number of participants; RSVPreF3, respiratory syncytial virus prefusion protein vaccine.
Figure 3.
Figure 3.
Solicited administration site and systemic events postvaccination. Note, while no solicited fever was reported, there was an instance of fever as part of a serious adverse event of pyelonephritis within 7 days postvaccination. Abbreviations: AE, adverse event; CI, confidence interval; RSVPreF3, respiratory syncytial virus prefusion protein vaccine.
Figure 4.
Figure 4.
Safety outcomes in mothers (A) and infants (B). Abbreviations: AE, adverse event; AESI, AE of special interest; CI, confidence interval; MA-AE, medically attended AE; RSVPreF3, respiratory syncytial virus prefusion protein vaccine.
Figure 5.
Figure 5.
RSV-A and RSV-B nAb GMTs in mothers and infants. *, ** Difference statistically significant between the 60 and 120 µg RSVPreF3 groups (GMT ratios, *1.49 [95% CI, 1.11–2.01] and **1.41 [95% CI, 1.07–1.86]). Abbreviations: CI, confidence interval; ED, estimated dilution; GMT geometric mean titer; N, number of participants; nAb, neutralizing antibody; RSVPreF3, respiratory syncytial virus prefusion protein vaccine.
See this image and copyright information in PMC

References

    1. Li Y, Wang X, Blau DM, et al. . Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 2022; 399:2047–64. - PMC - PubMed
    1. Jorquera PA, Tripp RA. Respiratory syncytial virus: prospects for new and emerging therapeutics. Expert Rev Respir Med 2017; 11:609–15. - PubMed
    1. American Academy of Pediatrics . Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134:e620–38. - PubMed
    1. Sun Z, Pan Y, Jiang S, Lu L. Respiratory syncytial virus entry inhibitors targeting the F protein. Viruses 2013; 5:211–25. - PMC - PubMed
    1. American Academy of Pediatrics . Diagnosis and management of bronchiolitis. Pediatrics 2006; 118:1774–93. - PubMed

Publication types

Substances

Associated data